Transforming the Prevention and Control of H9N2 Avian Influenza

DIFF-H9N2 is a groundbreaking live attenuated vaccine powered by the world’s first M2 gene modification technology, designed to transform H9N2 prevention and control in poultry.

A $1 Billion+ Market Opportunity

The global avian influenza vaccine market exceeds $3 billion (Source: Market Research Future) but remains dominated by inactivated vaccines with inherent shortcomings:

 

• Mucosal Immunity Gap:Over 50% of avian pathogens enter through mucosal routes (respiratory or digestive tracts), yet inactivated vaccines fail to trigger protective mucosal immunity.
• Ongoing Transmission Risk:They cannot block viral replication or shedding, allowing vaccinated flocks to continue spreading the virus.
• Variable Efficacy: Maternal antibodies can interfere with the immune response, reducing effectiveness.

Why DIFF-H9N2 Stands Out

• Triple Immune Protection: Activates mucosal, humoral, and cellular immunity to block viral invasion at the first line of defense.
• Direct Mucosal Defense:Builds a robust barrier in the respiratory tract, reducing viral replication and transmission.
• Broad Cross-Protection: Effective against prevalent H9N2 variants.
• Needle-Free Administration: Intranasal, eye drop, or spray delivery eliminates injection stress, lowers labor costs, and improves vaccination compliance.
• Early & Comprehensive Protection:Safe for chicks and ducklings from day one, ensuring coverage throughout growth.
• Enhanced Biosafety: Prevents vaccine virus shedding while maintaining disease surveillance integrity.
  
  

Proven Performance

• NegligibleViral Shedding: Confirmed safe in SPF and commercial chicken studies.
• Strong Immune Response: Two doses induce high HI antibody levels (HI>29).
• Effective Despite Maternal Antibodies: Rapid immunity confirmed in field trials with 3,000 chickens.
• Challenge Protection:Complete protection against wild-type H9N2.
  
  

Global Partnership Opportunities

DIFF Biotech is seeking strategic partners to accelerate development, registration, and commercialization of DIFF-H9N2. Together, we can enhance poultry health, improve food security, and reduce the economic impact of avian influenza worldwide.

 Contact: bd@diff-biotech.com